Adverse drug reactions to antiretroviral therapy (ART): An experience of spontaneous reporting and intensive monitoring from ART centre in India

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 3, 2010, Pages 247-255

  Modayil, Retty Rajan ^a   Harugeri, Anand ^a   Parthasarathi, Gurumurthy ^d   Clin, Grad Dip ^a   Ramesh, Madhan ^a   Prasad, Rajendra ^b   Naik, Vasudeva ^b   Giriyapura, Vamadeva ^c  

^a JSS COLLEGE OF PHARMACY   (India)

^b MYSORE MEDICAL COLLEGE AND RESEARCH INSTITUTE   (India)

^c Karnataka State AIDS Prevention Society   (India)

^d NONE

Author keywords

Adverse drug reaction; Antiretroviral; Human immunodeficiency virus; Pharmacovigilance

Indexed keywords

EFAVIRENZ; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; STAVUDINE;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; BAYES THEOREM; CD4+ T LYMPHOCYTE; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG EXPOSURE; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; EDUCATIONAL STATUS; ERYTHEMA; FEMALE; FOOT EDEMA; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERLACTATEMIA; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INCIDENCE; INDIA; LIPODYSTROPHY; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAIL COLOR DEFECT; NAIL DISCOLO; PATIENT MONITORING; PERIPHERAL NEUROPATHY; PHYSICIAN; PREDICTOR VARIABLE; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; RATING SCALE; RISK FACTOR; SEX DIFFERENCE; STEVENS JOHNSON SYNDROME; TUBERCULOSIS; URTICARIA; VOMITING;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AMBULATORY CARE; ANTI-HIV AGENTS; BAYES THEOREM; EDUCATIONAL STATUS; FEMALE; HIV INFECTIONS; HUMANS; INDIA; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TUBERCULOSIS; YOUNG ADULT;

EID: 77649224929     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1907     Document Type: Article

References (47)

1. World Health Organization [home page on the internet]. c2008 [cited 2008 October 23]. Available from: URL: http://www.who.int/en/
2. Averting HIV and AIDS [home page on the internet]. 2008 November 26 [cited 2009 January 5]. Available from: URL: http://www.avert.org/
3. Cooper CL, Breau C, Laroche A, Lee C, Garber G. Clinical outcomes of first antiretroviral regimen in HIV/hepatitis C virus co-infection. HIV Med 2006; 7(1): 32-37.
4. Bachani D. 650 link ART centres planned under NACP-III. NACO News 2009; 5(1): 8.
5. National AIDS Control Organization. Ministry of Health and Family Welfare, Government of India. [home page on the internet]. 2009 August 26 [cited 2009 August 31]. Available from: URL: https:// nacoonline.org/NACO
6. Mayboom RH, Hekster YA, Egberts AC, Gribnau FW, Edwards IR. Causal or casual? The role of causality assessment in pharmacovigilance. Drug Saf 1997; 17(6): 374-389.
7. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30(2): 239-245.
8. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992; 49: 2229-2232.
9. Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm 1992; 27(6): 538.
10. International monitoring of adverse reactions to drugs. WHO Adverse Reaction Terminology, The Uppsala Monitoring Centre: Uppsala, 2007.
11. Evans SJW. Statistics: analysis and presentation of safety data. In Stephens' Detection Of New Adverse Drug Reactions (5th edn), Talbot J, Waller P (eds). JohnWiley&Sons, Ltd:West Sussex, 2004; 301-326.
12. Gonzalez-Martin G, Caroca CM, Paris E. Adverse drug reactions (ADRs) in hospitalized pediatric patients. A prospective study. Int J Clin Pharmacol Ther 1998; 36(10): 530-533.
13. Cooper JW. Adverse drug reaction - related hospitalizations of nursing facility patients: A 4 -year study. South Med J 1999; 92(5): 485-490.
14. May FW, Rowett DS, Gilbert AL, McNeece JI, Hurley E. Outcomes of an educational-outreach service for community medical practitioners: non-steroidal anti-inflammatory drugs. Med J Aust 1999; 170(10): 471-474.
15. Moore N, Lecointre D, Noblet C, Mabill M. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol 1998; 45(3): 301-308.
16. Mehta U, Durrheim DN, Blockman M, Kredo T, Gounden R, Barnes KI. Adverse drug reactions in adult medical inpatients in a South African hospital serving a community with a high HIV/AIDS prevalence: prospective observational study. Br J Clin Pharmacol 2008; 65(3): 396-406.
17. Melmon KL. Preventable drug reactions-causes and cures. N Engl J Med 1971; 284(24): 1361-1368.
18. Stephens MDB. Introduction. In Stephens' Detection of New Adverse Drug Reactions (5th edn), Talbot J, Waller P (eds). JohnWiley & Sons, Ltd: West Sussex, 2004; 1-91.
19. Khalili H, Dashti-Khavidaki S, Mohraz M, Etghani A, Almasi F. Antiretroviral induced adverse drug reactions in Iranian human immunodeficiency virus positive patients. Pharmacoepidemiol Drug Saf 2009; 18(9): 848-857.
20. Koduri PR, Parekh S. Zidovudine-related anemia with recticulocytosis. Ann Hematol 2003; 82(3): 184-185.
21. Huffam SE, Srasuebkul P, Zhou J, et al. Prior antiretroviral therapy experience protects against zidovudine-related anaemia. HIV Med 2007; 8(7): 465-471.
22. Sullivan PS, Hanson DL, Chu SY, Jones JL,Ward JW. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood 1998; 91: 301-308.
23. Curkendall SM, Richardson JT, Emons MF, Fisher AE, Everhard F. Incidence of anaemia among HIV-infected patients treated with highly active antiretroviral therapy. HIV Med 2007; 8(8): 483-490.
24. De Lazzari E, León A, Arnaiz JA, et al. Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts. HIV Med 2008; 9(4): 221-226.
25. Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN. Nevirapine and the risk of Stevens Johnson syndrome or toxic epidermal necrolysis. AIDS 2001; 15(14): 1843-1848.
26. Rahav G, Maayan S. Nail pigmentation associated with zidovudine: a review and report of a case. Scand J Infect Dis 1992; 24(5): 557-561.
27. John M, Moore CB, James IR, et al. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001; 15: 717-723.
28. Hocqueloux L, Alberti C, Feugeas JP, et al. Prevalence, risk factors and outcome of hyperlactataemia in HIV-infected patients. HIV Med 2003; 4(1): 18-23.
29. ter Hofstede HJ, Koopmans PP, Burger DM. Stavudine plasma concentrations and lipoatrophy. J Antimicrob Chemother 2008; 61(4): 933-938.
30. Lowe SH, Hassink EA, van Eck-Smit BL, Borleffs JC, Lange JM, Reiss P. Stavudine but not didanosine as part of HAART contributes to peripheral lipoatrophy: a substudy from the Antiretroviral Regimen Evaluation Study (ARES). HIV Clin Trials 2007; 8(5): 337-344.
31. Waters L, Nelson M. Long-term complications of antiretroviral therapy: lipoatrophy. Int J Clin Pract 2007; 61(6): 999-1014.
32. van Griensven J, De Naeyer L, Mushi T, et al. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda. Trans R Soc Trop Med Hyg 2007; 101(8): 793-798.
33. Bogner JR, Vielhauer V, Beckmann RA, et al. Stavudine versus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr 2001; 27(3): 237-244.
34. von Giesen HJ, Hefter H, Jablonowski H, Arendt G. Stavudine and the peripheral nerve in HIV-1 infected patients. J Neurol 1999; 246(3): 211-217.
35. Scarsella A, Coodley G, Shalit P, et al. Stavudine-associated peripheral neuropathy in zidovudine-naïve patients: effect of stavudine exposure and antiretroviral experience. Adv Ther 2002; 19(1): 1-8.
36. Smyth K, Affandi JS, McArthur JC, et al. Prevalence of and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993-2006. HIV Med 2007; 8(6): 367-373.
37. Fumaz CR, Munoz-Moreno JA, Molto J, et al. Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychological issues, and adherence. J Acquir Immune Defic Syndr 2005; 38(5): 560-565.
38. Murdoch DM, Venter WD, Feldman C, Van Rie A. Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS 2008; 22(5): 601-610.
39. Martinez E, Blanco JL, Arnaiz JA, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001; 15(10): 1261-1268.
40. de Maat MM, ter Heine R, van Gorp EC, Mulder JW, Mairuhu AT, Beijnen JH. Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment. AIDS 2003; 17(15): 2209-2214.
41. González de Requena D, Núñez M, Jiménez- Nácher I, Soriano V. Liver toxicity caused by nevirapine. AIDS 2002; 16(2): 290-291.
42. Piliero PJ, Purdy B. Nevirapine-induced hepatitis: a case series and review of the literature. AIDS Read 2001; 11(7): 379-382.
43. Lucena MI, García-Cortés M, Cueto R, Lopez-Duran J, Andrade RJ. Assessment of drug-induced liver injury in clinical practice. Fundam Clin Pharmacol 2008; 22(2): 141-158.
44. Guyot S, Hayoz D, Telenti A, Cavassini M. Peripheral oedema and high arterial blood flow as a complication of antiretroviral therapy. AIDS 2004; 18(2): 356-358.
45. Lin D, Tucker MJ, Rieder MJ. Increased adverse drug reactions to antimicrobials and anticonvulsants in patients with HIV infection. Ann Pharmacother 2006; 40(9): 1594-1601.
46. WHOADR database search interface [home page on the internet]. 2009 August 28 [cited 2009 August 31]. Available from: URL: https://vigisearch.who-umc.org/
47. Meyboom RH, Lindquist M, Egberts AC, Edwards IR. Signal selection and follow-up in pharmacovigilance. Drug Saf 2002; 25(6): 459-465.